Navigation Links
CVS Caremark and Universal American Announce Termination of Hart-Scott-Rodino Waiting Period
Date:3/1/2011

WOONSOCKET, R.I. and RYE BROOK, N.Y., March 1, 2011 /PRNewswire/ -- In connection with the previously announced acquisition of the Medicare Part D business of Universal American (NYSE: UAM) by CVS Caremark (NYSE: CVS), both companies announced today that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Act. This represents a significant step forward towards completion of the transaction.

(Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO)

(Logo: http://photos.prnewswire.com/prnh/20110301/NE56560LOGO)

The transaction is expected to close by the end of the second quarter of 2011 and is subject to customary closing conditions, including approval of Universal American shareholders and state regulatory approvals.

"With this step, we are much closer to furthering CVS Caremark's position as a significant player in one of the nation's fastest growing segments of the Pharmacy Benefit Management industry. Now that we have achieved this important milestone, we look forward to closing the deal in the next several months," said Per Lofberg, President of Caremark Pharmacy Services. "We believe that bringing together these two businesses will strengthen our competitive offerings, enabling us to provide Medicare beneficiaries with expanded products and services and lower the cost of pharmacy care.  Today's approval puts us well on our way to accomplishing our goal."

Additional InformationIn connection with the proposed transaction, a newly formed subsidiary of Universal American ("NewCo") will file with the SEC a Registration Statement on Form S-4 that will include a proxy statement of Universal American that also constitutes a prospectus of NewCo. Universal American will mail the proxy statement/prospectus to its shareholders. BEFORE MAKING ANY VOTING DECISION, SHAREHOLDERS OF UNIVERSAL AMERICAN ARE URGED TO READ THE PROXY STATEMENT CAREFULLY BECAUSE THE PROXY STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. You may obtain copies of all documents filed with the SEC regarding this transaction, free of charge, at the SEC's website (www.sec.gov). You will also be able to obtain these documents, free of charge, when filed, from Universal American's website, www.universalamerican.com, under the tab "Investors" and then under the tab "SEC Filings."

CVS Caremark and Universal American and their respective directors, executive officers and certain other members of management and employees may be soliciting proxies from Universal American shareholders in favor of the merger and the separation. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the Universal American shareholders in connection with the proposed transaction will be set forth in the proxy statement/prospectus when it is filed with the SEC. You can find information about CVS Caremark's directors and executive officers in its definitive proxy statement filed with the SEC on March 29, 2010 and its Annual Report on Form 10-K for the year ended December 31, 2009 filed with the SEC on February 26, 2010, respectively. You can find information about Universal American's executive officers and directors in its definitive proxy statement filed with the SEC on April 30, 2010.

About CVS CaremarkCVS Caremark is the largest pharmacy health care provider in the United States. Through our integrated offerings across the entire spectrum of pharmacy care, we are uniquely positioned to provide greater access, to engage plan members in behaviors that improve their health and to lower overall health care costs for health plans, plan sponsors and their members. CVS Caremark is a market leader in mail order pharmacy, retail pharmacy, specialty pharmacy, and retail clinics, and is a leading provider of Medicare Part D Prescription Drug Plans. As one of the country's largest pharmacy benefits managers (PBMs), we provide access to a network of approximately 65,000 pharmacies, including more than 7,100 CVS/pharmacy® stores that provide unparalleled service and capabilities. Our clinical offerings include our signature Pharmacy Advisor program as well as innovative generic step therapy and genetic benefit management programs that promote more cost effective and healthier behaviors and improve health care outcomes. General information about CVS Caremark is available through the Company's Web site at http://info.cvscaremark.com/.

CVS Caremark Forward-looking StatementThis press release contains certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. For these statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2009 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q. CVS Caremark Contacts:Eileen Howard BooneCorporate Communications(401) 770-4561  Carolyn CastelCorporate Communications(401) 770-5717ccastel@cvs.comNancy ChristalInvestor Relations(914) 722-4704About Universal American Corp. Universal American, through our family of healthcare companies, offers health benefit plans designed to promote collaboration among our members and their healthcare professionals. This Healthy Collaboration(SM) improves, each day, the health and well-being of more than two million older and disabled Americans. For more information on Universal American, please visit our website at www.UniversalAmerican.com.

Universal American Forward Looking Statements This news release contains "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. Statements in this news release that are not historical facts are hereby identified as forward-looking statements and intended to be covered by the safe harbor provisions of the PSLRA and can be identified by the use of the words "believe," "expect," "predict," "project," "potential," "estimate," "anticipate," "project," "should," "intend," "may," "will," and similar expressions or variations of such words, or by discussion of future financial results and events, strategy or risks and uncertainties, trends and conditions in the Company's business and competitive strengths, all of which involve risks and uncertainties.

Where, in any forward-looking statement, we or our management expresses an expectation or belief as to future results or actions, there can be no assurance that the statement of expectation or belief will result or be achieved or accomplished. Our actual results may differ materially from our expectations, plans or projections. We warn you that forward-looking statements are only predictions and estimates, which are inherently subject to risks, trends and uncertainties, many of which are beyond our ability to control or predict with accuracy and some of which we might not even anticipate. These risks and uncertainties include: the timing to consummate the proposed transaction; negative effects from the pendency of the transaction; the risk that a condition to closing of the proposed transaction may not be satisfied; the risk that a regulatory approval that may be required for the proposed transaction is not obtained or is obtained subject to conditions that are not anticipated; the ability of Universal American to timely receive the required approval of its shareholders; the risk that the contemplated transaction does not occur for any other reason; the possibility that costs or difficulties related to the separation of the Medicare Prescription Drug Business will be greater than expected; the risks to NewCo's ability to effectively operate its businesses independently of the Medicare Prescription Drug Business, including its ability to access sufficient sources of capital to fund its operations; the risks to NewCo's ability to retain and hire key personnel; the diversion of management time on transaction-related issues and other risks described in the risk factor section of our SEC reports. We give no assurance that we will achieve our expectations and we do not assume responsibility for the accuracy and completeness of the forward-looking statements. Future events and actual results, financial and otherwise, may differ materially from the results discussed in the forward-looking statements as a result of many factors, including the risk factors described in the risk factor section of our SEC reports. We caution readers not to place undue reliance on these forward-looking statements that speak only as of the date made. All forward-looking statements included in this release are based upon information available to Universal American as of the date of the release, and we assume no obligation to update or revise any such forward-looking statements.

Universal American Contacts Robert A. Waegelein Executive Vice President & Chief Financial Officer (914) 934-8820 Investor Relations Counsel: The Equity Group Inc. Linda Latman (212) 836-9609 www.theequitygroup.com
'/>"/>

SOURCE CVS Caremark
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CVS Caremark Awarded Pharmacy Benefit Management Institute Rx Benefit Innovation Award for Pharmacy Advisor Program
2. CVS Caremark Corporation to Hold Fourth Quarter 2010 Conference Call
3. CVS Caremark Study Evaluates Which Pharmacy Channel Consumers Choose When Given Choice of Mail or Retail Prescriptions
4. CVS Caremark Announces Interim Leadership for Retail Business
5. CVS Caremark Study Finds Patients with Complex Therapies Struggle to Stay Adherent to their Medications
6. CVS Caremark Study Finds Medication Adherence Leads to Lower Health Care Costs, Even After Accounting for Increased Prescription Drug Spending
7. CVS CAREMARK to Purchase Universal Americans Medicare Part D Business
8. CVS Caremark to Present at the 29th Annual J.P. Morgan Healthcare Conference
9. New CVS Caremark Study Finds Health Information Technology May Help Promote Adherence, But More Information and Direction Needed
10. CVS Caremark Customer Care Team Awarded Silver Medal for Best Customer Service at Contact Center Worlds Global Top Ranking Performers Conference
11. CVS Caremark Research Finds Correlation Between Amount of Patient Co-pay and Prescription Abandonment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 9, 2016 Research and Markets has ... report to their offering. ... The report forecasts the global optical transceiver market ... The report covers the present scenario and the ... calculate the market size, the report considers the revenue generated from ...
(Date:12/9/2016)... Japan , Dec. 9, 2016 Mitsubishi ... ; President & Representative Director, CEO: Dr. Masayuki ... amyotrophic lateral sclerosis (ALS) given edaravone intravenously in 10-14 ... loss as measured by the ALS Functional Rating Scale-Revised ... International Symposium on ALS/MND in Dublin, ...
(Date:12/9/2016)... 2016 Research and Markets has announced the ... to their offering. ... The global travel vaccines market to grow at a CAGR ... the present scenario and the growth prospects of the global travel ... considers the revenue generated from the sales of various vaccines administered ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name Medical ... York, NY, on December 3rd, to benefit Holy Name Medical Center's programs and ... which raised over $1 million - the largest event in the Center's history, ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical ... 2017. The name change aligns the entire company with its existing Quality ... quality. , “We are very proud of the achievements associated with the West ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , a New ... Conventional Data Capture Methods for Input to Electronic Health Records: A Comparative Usability ... the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching ... innovative Unified Instance Manager architecture, meeting the needs of multichannel growth and ... the unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, ...
Breaking Medicine News(10 mins):